Amneal Starts Seeking International Partners
Part Of A Turnaround Plan Under Patels
Executive Summary
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
You may also be interested in...
Amneal Reveals Orion As European Partner
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.
Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.
Amneal Wins Race For US NuvaRing Rival
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.